Phase 3, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Dexamethasone+Lenalidomide+Carfilzomib (KRd), Lenalidomide Not-Refractory
### Instruction:
Identify the study with the following condition. 
### Input:
Phase 3, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Dexamethasone+Lenalidomide+Carfilzomib (KRd), Lenalidomide Not-Refractory 
### Output:
Popular Name is ASPIRE, Study ID is NCT01080391